Development and validation of a novel nomogram to predict the overall survival of patients with large cell lung cancer: A surveillance, epidemiology, and end results population-based study
Hongxia Zhou,
Pengxiang Gao,
Fangpeng Liu,
Liangliang Shi,
Longhua Sun,
Wei Zhang,
Xinping Xu,
Xiujuan Liu
Affiliations
Hongxia Zhou
Department of Nephrology, The 908th Hospital of the People's Liberation Army Joint Logistics Support Force, The Great Wall Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi 330006, China
Pengxiang Gao
Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province 330006, China
Fangpeng Liu
Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province 330006, China
Liangliang Shi
Medical Center of Burn Plastic and Wound Repair, The First Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province 330006, China
Longhua Sun
Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province 330006, China
Wei Zhang
Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province 330006, China; Jiangxi Institute of Respiratory Diseases, The First Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province 330006, China; Jiangxi Clinical Research Center for Respiratory Diseases, The First Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province 330006, China
Xinping Xu
Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province 330006, China; Jiangxi Institute of Respiratory Diseases, The First Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province 330006, China; Jiangxi Clinical Research Center for Respiratory Diseases, The First Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province 330006, China; Corresponding author. Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province 330006, China.
Xiujuan Liu
Department of Nephrology, The 908th Hospital of the People's Liberation Army Joint Logistics Support Force, The Great Wall Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi 330006, China; Corresponding author.
Background: Large cell lung cancer (LCLC) is a rare subtype of non-small cell lung carcinoma (NSCLC), and little is known about its clinical and biological characteristics. Methods: LCLC patient data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015. All patients were randomly divided into a training group and a validation group at a ratio of 7:3. The independent prognostic factors that were identified (P < 0.01) by stepwise multivariate Cox analysis were incorporated into an overall survival (OS) prediction nomogram, and risk-stratification systems, C-index, time-ROC, calibration curve, and decision curve analysis (DCA) were applied to evaluate the quality of the model. Results: Nine factors were incorporated into the nomogram: age, sex, race, marital status, 6th AJCC stage, chemotherapy, radiation, surgery and tumor size. The C-index of the predicting OS model in the training dataset and in the test dataset was 0.757 ± 0.006 and 0.764 ± 0.009, respectively. The time-AUCs exceeded 0.8. The DCA curve showed that the nomogram has better clinical value than the TNM staging system. Conclusions: Our study summarized the clinical characteristics and survival probability of LCLC patients, and a visual nomogram was developed to predict the 1-year, 3-year and 5-year OS of LCLC patients. This provides more accurate OS assessments for LCLC patients and helps clinicians make personal management decisions.
